8037 — China Biotech Services Holdings Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$274.52m
- HK$330.80m
- HK$211.99m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -110 | 203 | 181 | 863 | -142 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 36.5 | 7 | 17.2 | -11.3 | 30.3 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 22.6 | 172 | -225 | -435 | 251 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -30.3 | 422 | 40.5 | 483 | 195 |
Capital Expenditures | -7.35 | -127 | -12.2 | -122 | -62.9 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -92.9 | 0.352 | 4.09 | -135 | -4.65 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -100 | -126 | -8.12 | -256 | -67.5 |
Financing Cash Flow Items | 0.327 | -3.79 | -219 | -303 | -162 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 23.1 | 43.9 | -267 | -282 | -146 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -109 | 339 | -234 | -57.8 | -20.7 |